Medically reviewed by Faisal Shafiq (Superintendent Pharmacist, GPhC registration number 2067224)
This guide covers cellular receptors and signaling pathways targeted by vision peptides, detailed mechanisms for specific peptides (BPC-157, Cerebrolysin, GHK-Cu, Thymosin Beta-4), understanding blood-retinal barrier penetration and peptide delivery challenges, gene expression changes induced by peptide treatment, comparing peptide mechanisms to conventional eye medications, dose-response relationships and optimal timing considerations, synergistic mechanisms when combining multiple peptides, and translating mechanistic understanding into practical treatment protocols
C., Coy E., Frampton M
By delivering medications directly into the bloodstream, they are not subject to the first-pass metabolism in the liver, which can significantly reduce their potency
was briefly on WADA watch list TB-500 Not approved Prohibited Research use only Thymosin Alpha-1 Not approved in US Permitted Approved in some countries (Italy, China) Ipamorelin Not approved Prohibited Research use only Key point: None of these compounds are FDA-approved for human therapeutic use in the United States